Celularity (CELU) Stock Price, News & Analysis

Company Overview

Celularity, Inc. (NASDAQ: CELU) is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf cell therapies leveraging placental-derived cells and proprietary technology platforms. The company’s lead programs address oncology, infectious disease and regenerative medicine, with a particular emphasis on natural killer (NK) cell therapies designed to target hematologic malignancies and solid tumors. Celularity’s approach aims to deliver potent immunotherapeutic and regenerative solutions through scalable cell banks rather than patient-specific products.

Among its pipeline candidates is CYNK-001, an off-the-shelf NK cell therapy in development for a range of blood cancers and solid tumors, and the CELL-001 platform, featuring mesenchymal-like cells intended to support tissue repair and immune modulation. In parallel, Celularity is advancing red blood cell therapies derived from placental stem cells, with the goal of addressing shortages in transfusion medicine. These investigational products leverage the inherent regenerative and immunomodulatory properties of placental cells to offer potential advantages in consistency, availability and cost over autologous approaches.

Founded in 2018 as a spin-out from Celgene’s cell therapy operations, Celularity was co-founded by Dr. Robert Hariri, a physician-scientist with extensive experience in immunology and regenerative medicine, and investor Kevin Kimberlin. The company’s leadership team combines deep expertise in cell biology, clinical development, regulatory affairs and manufacturing. Under the guidance of its board and executive officers, Celularity completed a public listing through a SPAC merger in 2020 and has since established strategic partnerships to advance its clinical programs.

Headquartered in Florham Park, New Jersey, with additional research, development and manufacturing facilities in Warren, New Jersey, Celularity also collaborates with clinical and commercial partners in Asia and Europe. The company places strong emphasis on compliant, scalable GMP manufacturing and robust quality systems to support ongoing global clinical trials and anticipated product approvals, positioning itself to bring innovative cell therapies to patients worldwide.

Key Stats

• Today's Range: $1.84 to $1.94
• 50-Day Range: $1.48 to $2.49
• 52-Week Range: $1.00 to $5.22
• Volume: 29,627 shs
• Average Volume: 338,671 shs
• Market Capitalization: $45.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Celularity Stock Analysis - MarketRank™

Celularity scored higher than 2% of companies evaluated by MarketBeat, and ranked 919th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Celularity.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Celularity is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celularity is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Celularity has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.43% of the float of Celularity has been sold short.

Short Interest Ratio / Days to Cover

Celularity has a short interest ratio ("days to cover") of 19, which indicates bearish sentiment.

Change versus previous month

Short interest in Celularity has recently decreased by 2.70%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celularity does not currently pay a dividend.

Dividend Growth

Celularity does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.43% of the float of Celularity has been sold short.

Short Interest Ratio / Days to Cover

Celularity has a short interest ratio ("days to cover") of 19, which indicates bearish sentiment.

Change versus previous month

Short interest in Celularity has recently decreased by 2.70%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Sentiment

Celularity has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Celularity this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Celularity insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.10% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 19.02% of the stock of Celularity is held by institutions.

CELU Stock Analysis - Frequently Asked Questions

How have CELU shares performed this year?

Celularity's stock was trading at $2.08 at the beginning of 2025. Since then, CELU stock has decreased by 9.1% and is now trading at $1.89.

How were Celularity's earnings last quarter?

Celularity, Inc. (NASDAQ:CELU) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.91. The firm earned $18.13 million during the quarter, compared to the consensus estimate of $5.20 million. Celularity had a negative trailing twelve-month return on equity of 271.88% and a negative net margin of 106.77%.

When did Celularity's stock split?

Celularity shares reverse split before market open on Thursday, February 29th 2024.The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Celularity?

Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Celularity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celularity investors own include NVIDIA (NVDA), Meta Platforms (META), Lovesac (LOVE), MannKind (MNKD), PayPal (PYPL), Tesla (TSLA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 7/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CELU
• CIK: 1752828
• Web: www.celularity.com
• Phone: 908-768-2170
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.89 million
• Net Margins: -106.77%
• Pretax Margin: -106.77%
• Return on Equity: -271.88%
• Return on Assets: -42.82%

Debt

• Debt-to-Equity Ratio: 4.07
• Current Ratio: 0.38
• Quick Ratio: 0.28

Sales & Book Value

• Annual Sales: $54.22 million
• Price / Sales: 0.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: 5.08

Miscellaneous

• Outstanding Shares: 23,950,000
• Free Float: 18,656,000
• Market Cap: $45.03 million
• Optionable: Optionable
• Beta: 0.74